Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05882214
Other study ID # Alleviate a hangover with NMN
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date March 1, 2024
Est. completion date July 18, 2026

Study information

Verified date February 2024
Source Zhejiang Chinese Medical University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this double-blinded, randomized, crossover trial is to investigate the effects of NMN supplementation on liver function, liver fat content and lipid metabolism in healthy young subjects with acute binge drink. The main questions it aims to answer are: 1. if NMN administration could accelerate alcohol metabolism and alleviate hangover symptom; 2. if NMN administration could alleviate alcohol-induced liver injury and hepatic steatosis.


Description:

The goal of this double-blinded, randomized, crossover trial is to investigate the effects of NMN supplementation on liver function, liver fat content and lipid metabolism in healthy young subjects with acute binge drink. The main questions it aims to answer are: 1. if NMN administration could accelerate alcohol metabolism and alleviate hangover symptom; 2. if NMN administration could alleviate alcohol-induced liver injury and hepatic steatosis. Participants will be randomized into two groups (n=20), and take 4 NMN capsules (250mg/capsule) or 4 placebo capsules (maltodextrin), respectively. 15 minutes later, they are successively provided with same breakfast and then vodka with a dose of 1g/kg body weight. Venous blood are collected at 0h, 1h, 2h, 3h, 4h, 8h, 12h and 24h from each subject, respectively. In addition, nuclear magnetic resonance imaging (MRI) are taken at 0h, 4h and 24h after alcohol intake. After a 7-day washout period, volunteers are crossed over to another alternative group to receive the corresponding capsules and the test protocol repeats twice.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 20
Est. completion date July 18, 2026
Est. primary completion date July 19, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 30 Years
Eligibility 1. Inclusion Criteria: a. Sign informed consent 2. Exclusion Criteria: 1. Neurological disorders 2. Alcohol allergy 3. Alcohol addiction 4. Gastrointestinal diseases 5. Liver, kidney, cardiovascular or systemic diseases 6. Antibiotics were administered within 2 weeks prior to the trial 7. Participants who ate a vegetarian diet 8. Unable to use a smartphone or computer with Internet access 9. Participate in another intervention study

Study Design


Intervention

Dietary Supplement:
ß-nicotinamide Mononucleotide
After an 8-hour overnight fast, the participants ingested ß-nicotinamide Mononucleotide capsules with a single morning dose of 1000mg. The purity of ß-nicotinamide Mononucleotide capsules was no less than 97% according to high-performance liquid chromatography analysis.
Maltodextrin
After an 8-hour overnight fast, the participants ingested maltodextrin capsules with a single morning dose of 1000mg.

Locations

Country Name City State
China Zhejiang Chinese Medical University Hangzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
Zhejiang Chinese Medical University

Country where clinical trial is conducted

China, 

References & Publications (5)

Kim H, Kim YJ, Jeong HY, Kim JY, Choi EK, Chae SW, Kwon O. A standardized extract of the fruit of Hovenia dulcis alleviated alcohol-induced hangover in healthy subjects with heterozygous ALDH2: A randomized, controlled, crossover trial. J Ethnopharmacol. 2017 Sep 14;209:167-174. doi: 10.1016/j.jep.2017.07.028. Epub 2017 Jul 24. — View Citation

Lee MH, Kwak JH, Jeon G, Lee JW, Seo JH, Lee HS, Lee JH. Red ginseng relieves the effects of alcohol consumption and hangover symptoms in healthy men: a randomized crossover study. Food Funct. 2014 Mar;5(3):528-34. doi: 10.1039/c3fo60481k. — View Citation

Mammen RR, Natinga Mulakal J, Mohanan R, Maliakel B, Illathu Madhavamenon K. Clove Bud Polyphenols Alleviate Alterations in Inflammation and Oxidative Stress Markers Associated with Binge Drinking: A Randomized Double-Blinded Placebo-Controlled Crossover Study. J Med Food. 2018 Nov;21(11):1188-1196. doi: 10.1089/jmf.2017.4177. Epub 2018 Sep 20. — View Citation

Torp N, Israelsen M, Nielsen MJ, Astrand CP, Juhl P, Johansen S, Hansen CD, Madsen B, Villesen IF, Leeming DJ, Thiele M, Hansen T, Karsdal M, Krag A. Binge drinking induces an acute burst of markers of hepatic fibrogenesis (PRO-C3). Liver Int. 2022 Jan;42(1):92-101. doi: 10.1111/liv.15120. Epub 2021 Dec 10. — View Citation

Weissenborn R, Duka T. Acute alcohol effects on cognitive function in social drinkers: their relationship to drinking habits. Psychopharmacology (Berl). 2003 Jan;165(3):306-12. doi: 10.1007/s00213-002-1281-1. Epub 2002 Nov 19. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Ethanol concentration Ethanol concentration change in mg/dL of each set day1-2 and day 8-9 of each 30minutes and 1hour and 2 hours and 3 hours and 4 hours and 5 hours and 6 hours and 12 hours and 24 hours
Primary Acetaldehyde concentration Acetaldehyde concentration change in mg/dL of each set day1-2 and day 8-9 of each 30minutes and 1hour and 2 hours and 3 hours and 4 hours and 5 hours and 6 hours and 12 hours and 24 hours
Primary Hepatic fibrosis change Research blood hepatic fibrosis include:Hyaluronicacid in ng/mL;Laminin in ng/mL;type ? in ng/mL;precollagen in ng/mL;type ? collagen in ng/mL;Fibronect in ng/mL day1-2 and day 8-9 of each 30minutes and 1hour and 2 hours and 3 hours and 4 hours and 5 hours and 6 hours and 12 hours and 24 hours
Primary hepatic function change Research blood hepatic function include:TBIL in µmol/L;Direct bilirubin in µmol/L;Indirect bilirubin in µmol/L;Total bile acid in µmol/L day1-2 and day 8-9 of each 30minutes and 1hour and 2 hours and 3 hours and 4 hours and 5 hours and 6 hours and 12 hours and 24 hours
Primary hepatic injury change Research blood hepatic injury include:Alanine Aminotransferase in U/L;Aspartate Aminotransferase in U/L;Gamma-Glutamyltransferase in U/L;Alpha-Fucosidase in U/L;Alkaline Phosphatase in U/L;cholinesterase in U/L;Lactate Dehydrogenase Enzyme in U/L day1-2 and day 8-9 of each 30minutes and 1hour and 2 hours and 3 hours and 4 hours and 5 hours and 6 hours and 12 hours and 24 hours
Primary Lipid metabolism change Research blood Fat metabolism include:Triglycerides in mmol/L;HDL-Cholesterol in mmol/L;LDL--Cholesterol in mmol/L;Apolipoprotein A in mmol/L;Apolipoprotein B in mmol/L;Lipoprotein(a) in mmol/L day1-2 and day 8-9 of each 30minutes and 1hour and 2 hours and 3 hours and 4 hours and 5 hours and 6 hours and 12 hours and 24 hours
Primary hangover cognition assessment tools after drinking The survey tool consisted of many questions addressing cognition headache, nausea,vomiting,fatigue,concentration,thirst or dehydration,light sensitivity,sleeping difficulty,excessive sweating,anxiety,feelings of depression,trembling or shaking,dizziness,stomachache,and memory loss after drinking day1-2 and day 8-9 of each 30minutes and 1hour and 2 hours and 3 hours and 4 hours and 5 hours and 6 hours and 12 hours and 24 hours
Secondary Laboratory markers of inflammation Research blood Inflammatory factor include:Interleukin-2 in pg/ml;Interleukin-4 in pg/ml;Interleukin-6 in pg/ml;Interleukin-8 in pg/ml;Interleukin-10 in pg/ml;Tumor necrosis factor in pg/ml;Interferon gamma in pg/ml;Human IL-1 beta protein in pg/ml;High Sensitivity C-reactive Protein in mg/L day1-2 and day 8-9 of each 30minutes and 1hour and 2 hours and 3 hours and 4 hours and 5 hours and 6 hours and 12 hours and 24 hours
Secondary nicotinamide adenine dinucleotide metabolism change NAD+ metabolism will be analysed by performing Liquid Chromatography Mass Spectrometer(LC-MS) on serum day1-2 and day 8-9 of each 30minutes and 1hour and 2 hours and 3 hours and 4 hours and 5 hours and 6 hours and 12 hours and 24 hours
Secondary Fecal metabolites Gut microbial communities and their abundant features will be analysed based on shotgun metagenomic sequencing. day1-2 and day 8-9 of each set
Secondary Metabolomics profiling Targeted metabonomics are analyzed based on urine and faeces at all visits day1-2 and day 8-9 of each set
See also
  Status Clinical Trial Phase
Recruiting NCT05480696 - Soluble Fibre Supplementation in NAFLD Phase 1
Completed NCT05124847 - TREating Pediatric Obesity N/A
Recruiting NCT05499585 - Treating Pediatric NAFLD With Nutrition N/A
Completed NCT03717935 - Oral Amino Acid Nutrition to Improve Glucose Excursions in PCOS N/A
Active, not recruiting NCT02493153 - Hepatic Steatosis After Cholecystectomy N/A
Active, not recruiting NCT05654051 - The SLIM LIVER Study Phase 2
Completed NCT03334214 - Safety, Tolerability, and Pharmacodynamics of IONIS-DGAT2Rx in Adult Patients With Type 2 Diabetes Phase 2
Enrolling by invitation NCT02816814 - Lacto-ovo-vegetarian Diet Riched in Omega-3 Fatty Acids in Menopausal Women N/A
Active, not recruiting NCT03587727 - Hepatic Mitochondrial Function in Youth
Not yet recruiting NCT06363617 - Implementation of the Fatty Liver Index in Primary Care N/A
Not yet recruiting NCT05935826 - Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study) N/A
Not yet recruiting NCT06394206 - Benefit of a Hospital Intervention in Patients With Hepatic Steatosis N/A
Recruiting NCT03142698 - Evaluation of 4 MRI Methods (PDFF 3, 6 and 11 Gradient Echoes and Spectroscopy) Compared to the Reference Method (Liver Biopsy) in Quantification of Hepatic Steatosis N/A
Completed NCT00480922 - Effects of a Low Glycemic Load Diet on Fatty Liver in Children N/A
Not yet recruiting NCT05871749 - Effects of Hepatic Fibrosis on Hepatic Steatosis Using the Ultrasound Attenuation Imaging in Chronic Hepatitis B
Recruiting NCT05897073 - Time-Restricted Eating, Exercise and Cardiometabolic Health in Obesity N/A
Completed NCT03961516 - Glycemic Characterization and Pancreatic Imaging Correlates in Cystic Fibrosis
Completed NCT04180631 - Quantitative US for Hepatic Steatosis N/A
Terminated NCT00845845 - Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH) Phase 2
Completed NCT02814240 - Hepatic Steatosis and Pituitary Gland Failure, Evaluation by Nuclear Magnetic Resonance (NMR) Imaging N/A